Is Compass Therapeutics (CMPX) Quietly Rewriting Its Oncology Strategy With New Commercial and Medical Chiefs? [Yahoo! Finance]
Compass Therapeutics, Inc. (CMPX)
Company Research
Source: Yahoo! Finance
January 1, 2026, adding deep oncology commercialization and clinical development experience to its leadership team. The pairing of a commercially seasoned oncology executive with a gastrointestinal-focused immuno-oncology development leader may sharpen Compass's path from clinical programs to potential market-ready therapies. We'll now examine how the addition of a proven oncology commercial leader shapes Compass Therapeutics' broader investment narrative and future execution. AI is about to change healthcare. These 108 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. For Compass Therapeutics, the core belief you need to have is that its immuno-oncology pipeline can eventually convert scientific promise into commercial products despite ongoing losses and no current revenue. The recent hiring of Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chi
Show less
Read more
Impact Snapshot
Event Time:
CMPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMPX alerts
High impacting Compass Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CMPX
News
- Assessing Compass Therapeutics (CMPX) Valuation After Strong 1 Year Share Price Performance [Yahoo! Finance]Yahoo! Finance
- Compass Therapeutics Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Compass Therapeutics (NASDAQ:CMPX) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Compass Therapeutics (NASDAQ:CMPX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.MarketBeat
- Compass Therapeutics Provides Corporate UpdateGlobeNewswire
CMPX
Earnings
- 8/11/25 - Miss
CMPX
Sec Filings
- 1/12/26 - Form 4
- 1/8/26 - Form EFFECT
- 1/6/26 - Form 8-K
- CMPX's page on the SEC website